Celgene Business Development at a Glance

Last Modified Date: February 22, 2018

Celgene started 2018 with billion dollar acquisitions of two companies: Impact Biomedicines and Juno Therapeutics.

Impact Biomedicines was acquired for its fedratinib asset, which has now been passed from private company to pharma giant twice over.

Juno Therapeutics was acquired for its engineered T cell therapies, a deal that was hardly surprising in light of Novartis' success with Kymriah, the acquisition of Kite Pharma by Gilead Sciences, and the fact that Celgene already owned equity in Juno.

With these new rockstars in its stable, Celgene must now focus on bringing them successfully to market while keeping an eye out for other promising assets to add to its pipeline.

Celgene Stock

Celgene Corporation
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 12 042M
Therapeutic Focus: Hematology and Liquid Tumors, Inflammation and Immunology, Solid Tumors


DEAL ACTIVITY

Celgene Data

Figure 1. Celgene Corporation. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

ACQUISITION OF JUNO THERAPEUTICS FOR CAR-T AND TCR ASSETS

Total Size: USD 9 000M | Therapeutic Area: Hematology and Liquid Tumors | Date: January 2018

PRESS 2018 | PRESS 2016 | PRESS 2015 | SEC

ACQUISITION OF IMPACT BIOMEDICINES FOR HEMATOLOGY ASSET

Total Size: USD 2 250M | Upfront: USD 1 100M | Therapeutic Area: Hematology and Liquid Tumors | Date: January 2018

PRESS

COLLABORATION WITH NIMBUS THERAPEUTICS FOR TYK2 AND STING ANTAGONIST ASSETS

Therapeutic Area: Inflammation and Immunology | Date: October 2017

PRESS

R&D PIPELINE

Celgene Pipeline

Figure 2. Celgene Corporation. R&D Pipeline at Present (February 2018)

Products from Recent Deals:

TRIPHASE ACCELERATOR PARTNERED PROTEASOME INHIBITOR

Disease Area: Solid Tumors | Status: Glioblastoma Combination Therapy Phase III | Malignant Glioma and Glioblastoma Combination Therapy Phase II

ACQUIRED RECEPTOS SELECTIVE SPHINGOSINE 1-PHOSPHATE 1 AND 5 RECEPTOR MODULATOR

Disease Area: Inflammation and Immunology | Status: Multiple Sclerosis Phase III | Ulcerative Colitis Phase III | Crohn's Disease Phase III

LYCERA PARTNERED ROR-GAMMA AGONIST COMPOUNDS

Disease Area: Inflammation and Immunology, Solid Tumors | Status: Ulcerative Colitis Phase II | Locally Advanced or Metastatic Cancer Phase II | Non-Small Cell Lung Cancer Phase I

BUSINESS DEVELOPMENT TEAM

Where did the data come from? The data and visualizations in this post come from the MotionHall OutMatch predictive out-licensing software.

How can I see more? Join the MotionHall platform today to access business development insights gleaned from data and predictive analytics.